Hi, I have had spondylolisthesis since age 11 which left me with extreme nerve pain...restless leg syndrome. Had 3 spinal ops and also had hip surgery 2 years ago. have asthma and hypothyroidism. I can deal with everything else but this nerve pain is insane. Used Gabapentin for 9 years and now its not in the market in Nairobi, Kenya where I live. Am on Lyrica, which is not working. I started Cbd oil in August but now found my body has become immune to the effects of pain releif I was getting. Can anyone suggest what strength oil/cbd supplement I should aim for? Currently am making flapjacks with weed, have one every night but this makes me high which I dont want. I still wake up in pain at night, please help.
PHOENIX, AZ / ACCESSWIRE / March 6, 2019 / Uptick Newswire Stock Day Podcast welcomed Hemp Inc., (OTC PINK: HEMP) a company that seeks to build a business constituency for the American small farmer, the American veteran, and other groups experiencing the ever-increasing disparity between tapering income and soaring expenses. CEO, Bruce Perlowin, joined Stock Day host Everett Jolly. To begin the interview Perlowin explained that the Company began by demonstrating what can be developed with hemp, particularly in the industrial setting.
A non-intoxicating cannabinoid found in cannabis. After tetrahydrocannabinol (THC), cannabidiol (CBD) is the second-most abundant cannabinoid in the plant, and has many potential therapeutic benefits, including anti-inflammatory, analgesic, anti-anxiety and seizure-suppressant properties. Cannabidiol can be sourced from both marijuana plants and hemp plants, which are legal in most countries as they contain minor amounts of THC.  
With so many companies popping up every day, we’ve done the hard work for you. We bring you the best CBD oil guide and the top 25 brands that made our list based on CBD oil quality, effectiveness, customer service and of course price. Please note, this article is updated constantly, so don’t forget come back from time to time to see the most updated information.
Luke Zigovits, chief executive of Wisconsin-based Hemp Science, said, “We can finally relax. Because now we can source seed, now we can sell our product across state lines. Prohibition is over. It broadens horizons, allowing universities to do research, for example.” Beyond moving the industry into legitimacy, Zigovits said there are opportunities for tobacco farmers in Wisconsin and elsewhere to start growing industrial hemp crops as well.
I have to share this with you all, I live in Washington State where pot is legal to everyone of age except if your sign a Pain Contract. As we all know to well who suffer from chronic pain that taking or lowering our life saving pain medications is slowly killing us, but we need to all remember that our country and state and the CDC are all trying to save us from addiction. So to my ear, I heard on the radio an advertisement from a local pot shop on their quality products and then when you listen to it, then it goes on to say as fast as they can, it my lead to addiction, so use cautiously. WHAT, it may lead to addiction but those of us who tried everything else to ease our miserable pain to only find that pain medications is so far the only thing that gives us relief. But our government and states want to protect us from ourselves by taking away our much needed medications and in my state offer me instead marijuana that may cause addiction, I say that is so CRAZY! Let people young and old use marijuana either to get high or for help with medical conditions with the chance that they may become addicted to it but for me, who I have never ever abused my pain medications, we have to lower you because you could become addicted to it and it is dangerous for your health. I ask so if you lower me so low where I have to stay in bed all day because it hurts to much to walk and with my blood pressure up so high that I am a sitting duck for a stroke, that that isn’t unhealthy for me????? At least with the proper dosage that aids me to have some life is so much better for my health than not enough or not any. INSANITY TO THE FULLEST!
Cannabis (/ˈkænəbɪs/) is a genus of flowering plants in the family Cannabaceae. The number of species within the genus is disputed. Three species may be recognized: Cannabis sativa, Cannabis indica, and Cannabis ruderalis; C. ruderalis may be included within C. sativa; all three may be treated as subspecies of a single species, C. sativa;[1][2][3][4] or C. sativa may be accepted as a single undivided species.[5] The genus is widely accepted as being indigenous to and originating from Central Asia, with some researchers also including upper South Asia in its origin.[6][7]
So true. Hearst and Rockefeller did not want Hemp or any form of Cannabis interfering with their lucrative paper, pharmaceutical and oil industries. Hemp is versatile and renewable. It can be used for food, medicine, fuel, paper, clothing, plastic, building materials; just about anything paper and oil is used for. These bastard wealthy people have done a disservice to all people and for the sake of lining their already copiously rich pockets. They and those like them are criminals of the worst order
Nabilone (Cesamet) (Figure 1), is a synthetic dimethylheptyl analogue of THC (British Medical Association 1997) that displays greater potency and prolonged half-life. Serum levels peak in 1–4 hours (Lemberger et al 1982). It was also primarily developed as an anti-emetic in chemotherapy, and was recently re-approved for this indication in the USA. Prior case reports have noted analgesic effects in case reports in neuropathic pain (Notcutt et al 1997) and other pain disorders (Berlach et al 2006). Sedation and dysphoria were prominent sequelae. An RCT of nabilone in 41 post-operative subjects actually documented exacerbation of pain scores after thrice daily dosing (Beaulieu 2006) (Table 1). An abstract of a study of 82 cancer patients on nabilone claimed improvement in pain levels after varying periods of follow-up compared to patients treated without this agent (Maida 2007). However, 17 subjects dropped out, and the study was neither randomized nor controlled, and therefore is not included in Table 1.
High-CBD strains tend to deliver very clear-headed, functional effects without the euphoric high associated with high-THC strains. They’re typically preferred by consumers who are extremely sensitive to the side effects of THC (e.g., anxiety, paranoia, dizziness). A high-CBD strain would also be a great choice for someone needing to medicate throughout the day to control pain, inflammation, anxiety, or other chronic conditions.
Medical cannabis, or medical marijuana, can refer to the use of cannabis and its cannabinoids to treat disease or improve symptoms; however, there is no single agreed-upon definition.[39][40] The rigorous scientific study of cannabis as a medicine has been hampered by production restrictions and other federal regulations.[41] There is limited evidence suggesting cannabis can be used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, and to treat chronic pain and muscle spasms.[42][43][44] Its use for other medical applications is insufficient for conclusions about safety or efficacy.
According to the United States Department of Health and Human Services, there were 455,000 emergency room visits associated with cannabis use in 2011. These statistics include visits in which the patient was treated for a condition induced by or related to recent cannabis use. The drug use must be "implicated" in the emergency department visit, but does not need to be the direct cause of the visit. Most of the illicit drug emergency room visits involved multiple drugs.[76] In 129,000 cases, cannabis was the only implicated drug.[77][78]

Even those who are facing issues related to mental health should consult their physician. Research studies continue to examine the effects and benefits of this drug far beyond just anxiety and depression. The benefits for those facing schizophrenia may be just the tip of the iceberg, as this may help with such conditions as mania and other forms of psychosis with further research.
Truth be told, one of the biggest draws to using CBD oil for pain has been the fact that it has little distinguishable side-effects or contraindications with other medications. In fact, in a massive report that was published by the World Health Organization during last year’s 2017 Expert Committee on Drug Dependence, it was (finally) declared to the world that CBD is a “safe, well tolerated [compound, which] is not associated with any significant adverse public health effects.”

After completing your workout or postgame routine, you may feel worn down and sore. CBD Pain Freeze is a fast-acting, topical solution that can be applied directly to the skin for instant relief. Our invigorating CBD Rub provides a cooling sensation that can relax and alleviate joints and muscles worn down from physical activity. If you regularly stay active, our CBD Pain Freeze is a must have to heal up faster and feel reenergized.


Given CBD’s reputation as a popular, artisanal remedy, one would think that Epidiolex would command a lot of “off label” attention. After all, physicians often prescribe pharmaceuticals off label to treat conditions that were not the actual focus of clinical trials. But the costly price tag for Epidiolex (more than $30,000 annually) precludes off label prescribing as well as affordable access for tens of millions of Americans without health insurance.
"Both hemp and marijuana also have separate definitions in statute. While marijuana is defined in U.S. drug laws, Congress established a statutory definition for industrial hemp as “the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis” as part of the 2014 farm bill.4 Hemp is generally characterized by plants that are low in delta-9 tetrahydrocannabinol (delta-9 THC), the dominant psychotrophic ingredient in Cannabis sativa.5

Despite advanced analytical techniques, much of the cannabis used recreationally is inaccurately classified. One laboratory at the University of British Columbia found that Jamaican Lamb's Bread, claimed to be 100% sativa, was in fact almost 100% indica (the opposite strain).[83] Legalization of cannabis in Canada (as of October 17, 2018) may help spur private-sector research, especially in terms of diversification of strains. It should also improve classification accuracy for cannabis used recreationally. Legalization coupled with Canadian government (Health Canada) oversight of production and labelling will likely result in more—and more accurate—testing to determine exact strains and content. Furthermore, the rise of craft cannabis growers in Canada should ensure quality, experimentation/research, and diversification of strains among private-sector producers.[84]


Despite some relatively tough talk from regulatory bodies, it can seem like they’re trying to close the barn door after the horse got out. CBD is already everywhere, and people are curious about it for reasons that seem to go far beyond trendiness, such as financial precariousness and health-care costs. “People are panicking and looking for things. They’re like, ‘What if I don’t have insurance because I get laid off? What can I replace my meds with?’” says Donahue, the Allure editor. CBD fits neatly with a growing distrust in technology and in the pharmaceutical industry, and America’s moderating view of cannabis means that many people see CBD as a safer alternative for anxiety or pain that’s worth trying.
Quality is a particular concern, because cannabis plants easily soak up heavy metals from pesticides and other contaminants, Marcu says. If you are buying online, look for a company that documents how it tests its products. (If the website doesn’t indicate this, call and ask.) “Buying from a reputable manufacturer is crucial, because it matters how the plant is cultivated and processed,” Dr. Maroon says. One clue that a company is cutting corners: too low a cost. Good CBD is pricey—a bottle of high-quality capsules is sold in Cohen’s office for $140. But for many, it’s worth the money. Roth spent $60 on her tiny bottle. But when her energy returned the day she started taking CBD, she decided that was a small price to pay.

Among members of the public-health community, it is impossible to spend five minutes on the e-cigarette question without getting into an argument. And this is nicotine they are arguing about, a drug that has been exhaustively studied by generations of scientists. We don’t worry that e-cigarettes increase the number of fatal car accidents, diminish motivation and cognition, or impair academic achievement. The drugs through the gateway that we worry about with e-cigarettes are Marlboros, not opioids. There are no enormous scientific question marks over nicotine’s dosing and bio-availability. Yet we still proceed cautiously and carefully with nicotine, because it is a powerful drug, and when powerful drugs are consumed by lots of people in new and untested ways we have an obligation to try to figure out what will happen.
Hemp, or industrial hemp (from Old English hænep),[1] typically found in the northern hemisphere, is a variety of the Cannabis sativa plant species that is grown specifically for the industrial uses of its derived products.[2] It is one of the fastest growing plants[3] and was one of the first plants to be spun into usable fiber 10,000 years ago.[4] It can be refined into a variety of commercial items including paper, textiles, clothing, biodegradable plastics, paint, insulation, biofuel, food, and animal feed.[5]

The results of the three large European cohort studies have been confirmed in two smaller New Zealand birth cohorts. Arsenault and colleagues (2002) reported a prospective study of the relationship between adolescent cannabis use and psychosis in a New Zealand birth cohort (n = 759). They found a relationship between cannabis use by age 15 and an increased risk of psychotic symptoms by age 26. The relationship did not change when they controlled for other drug use, but it was no longer statistically significant after adjusting for psychotic symptoms at age 11. The latter probably reflected the small number of psychotic disorders observed in the sample. Fergusson et al. (2003) found a relationship between cannabis dependence at age 18 and later symptoms that included those in the psychotic spectrum reported at age 21 in the Christchurch birth cohort. Fergusson and colleagues adjusted for a large number of potential confounding variables, including self-reported psychotic symptoms at the previous assessment, other drug use and other psychiatric disorders, but whether the association represents a link between cannabis use and psychotic symptoms specifically, or more general psychiatric morbidity, remains unclear.
A 2015 review found that the use of high CBD-to-THC strains of cannabis showed significantly fewer positive symptoms such as delusions and hallucinations, better cognitive function and both lower risk for developing psychosis, as well as a later age of onset of the illness, compared to cannabis with low CBD-to-THC ratios.[279] A 2014 Cochrane review found that research was insufficient to determine the safety and efficacy to using cannabis to treat schizophrenia or psychosis.[280] As of 2017, the molecular mechanisms for the anti-inflammatory and possible pain relieving effects of cannabis are under preliminary research.[281]
"Comparisons of industrial hemp to hydrocarbon or other conventional industrial feedstocks show that, generally, hemp requires substantially less energy for manufacturing, often is suited to less-toxic means of processing, and provides competitive product performance (especially in terms of durability, light weight, and strength), greater recyclability and/or biodegradability, and a number of value-added applications for byproducts and waste materials at either end of the product life cycle."
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:
In 1988, the first cannabinoid receptor was identified (CB1) (Howlett et al 1988) and in 1993, a second was described (CB2) (Munro et al 1993). Both are 7-domain G-protein coupled receptors affecting cyclic-AMP, but CB1 is more pervasive throughout the body, with particular predilection to nociceptive areas of the central nervous system and spinal cord (Herkenham et al 1990; Hohmann et al 1999), as well as the peripheral nervous system (Fox et al 2001; Dogrul et al 2003) wherein synergy of activity between peripheral and central cannabinoid receptor function has been demonstrated (Dogrul et al 2003). CB2, while commonly reported as confined to lymphoid and immune tissues, is also proving to be an important mediator for suppressing both pain and inflammatory processes (Mackie 2006). Following the description of cannabinoid receptors, endogenous ligands for these were discovered: anandamide (arachidonylethanolamide, AEA) in 1992 in porcine brain (Devane et al 1992), and 2-arachidonylglycerol (2-AG) in 1995 in canine gut tissue (Mechoulam et al 1995) (Figure 1). These endocannabinoids both act as retrograde messengers on G-protein coupled receptors, are synthesized on demand, and are especially active on glutamatergic and GABA-ergic synapses. Together, the cannabinoid receptors, their endogenous ligands (“endocannabinoids”) and metabolizing enzymes comprise the endocannabinoid system (ECS) (Di Marzo et al 1998), whose functions have been prosaically termed to be “relax, eat, sleep, forget and protect” (p. 528). The endocannabinoid system parallels and interacts at many points with the other major endogenous pain control systems: endorphin/enkephalin, vanilloid/transient receptor potential (TRPV), and inflammatory. Interestingly, our first knowledge of each pain system has derived from investigation of natural origin analgesic plants, respectively: cannabis (Cannabis sativa, C. indica) (THC, CBD and others), opium poppy (Papaver somniferun) (morphine, codeine), chile peppers (eg, Capsicum annuum, C. frutescens, C. chinense) (capsaicin) and willow bark (Salix spp.) (salicylic acid, leading to acetylsalicylic acid, or aspirin). Interestingly, THC along with AEA and 2-AG, are all partial agonists at the CB1 receptor. Notably, no endocannabinoid has ever been administered to humans, possibly due to issues of patentability and lack of commercial feasibility (Raphael Mechoulam, pers comm 2007). For an excellent comprehensive review of the endocannabinoid system, see Pacher et al (2006), while Walker and Huang have provided a key review of antinociceptive effects of cannabinoids in models of acute and persistent pain (Walker and Huang 2002).
Apart from Endoca CBD oils, you will also find other similar products, such as isolate, tinctures or creams. Some products are designed for pets too. The range offered by Endoca is not impressive when compared to more prestigious manufacturers, but you can still find anything you might need. Using in house green equipment and procedures for the manufacturing process, Endoca can also afford to keep the prices a little lower.
"The survey covers the harvest of 2013, related to a total cultivation area of 15,700 ha. The first figure shows the development of the cultivation area since 1993. Between 1993 and 1996 the cultivation of industrial hemp was legalised in most of the member states, others followed later. In 2011 the cultivation area decreased to its lowest value since 1994 (ca. 8,000 ha), but increased in 2012, 2013 and 2014, to finally reach 25,000 ha in 2015. In 2016 a further increase is expected. The main cultivation member states are France and The Netherlands. In recent years, many new European countries started or expanded their hemp cultivation, mainly for the production of hemp seeds.
This Farm Bill gives Trump Administration a powerful tool in their bargaining with China. As I wrote earlier this year in Forbes, China produces 50% of the world’s cannabis supply, with a large majority of that supply being the THC-lacking hemp variety; this gives China “massive economic potential” which “poses a threat to cannabis interests around the world and particularly in the U.S. market.”

Hemp is thus profitable and sustainable, two words which have eluded many U.S. farmers as of late. Hemp cultivation could provide much-needed relief as farmers struggle to find markets for millions of bushels of crops during the trade wars. Now, instead of importing an estimated $100 million of hemp products every year, that money will go to American farmers and entrepreneurs.

A study by Henquet and colleagues (2004) substantially replicated both the Swedish and Dutch studies in a 4-year follow-up of a cohort of 2437 adolescents and young adults between 1995 and 1999 in Munich. They found a dose–response relationship between self-reported cannabis use at baseline and the likelihood of reporting psychotic symptoms. As in the Dutch cohort, young people who reported psychotic symptoms at baseline were much more likely to experience psychotic symptoms at follow-up if they used cannabis than were cannabis-using peers without such a history.
Cannabidiol is insoluble in water but soluble in organic solvents such as pentane. At room temperature, it is a colorless crystalline solid.[42] In strongly basic media and the presence of air, it is oxidized to a quinone.[43] Under acidic conditions it cyclizes to THC,[44] which also occurs during pyrolysis (smoking).[45] The synthesis of cannabidiol has been accomplished by several research groups.[46][47][48]
^ Jump up to: a b c Whiting, PF; Wolff, RF; Deshpande, S; Di Nisio, M; Duffy, S; Hernandez, AV; Keurentjes, JC; Lang, S; Misso, K; Ryder, S; Schmidlkofer, S; Westwood, M; Kleijnen, J (23 June 2015). "Cannabinoids for Medical Use: A Systematic Review and Meta-analysis" (PDF). JAMA. 313 (24): 2456–2473. doi:10.1001/jama.2015.6358. hdl:10757/558499. PMID 26103030.
Medical cannabis, or medical marijuana, can refer to the use of cannabis and its cannabinoids to treat disease or improve symptoms; however, there is no single agreed-upon definition.[39][40] The rigorous scientific study of cannabis as a medicine has been hampered by production restrictions and other federal regulations.[41] There is limited evidence suggesting cannabis can be used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, and to treat chronic pain and muscle spasms.[42][43][44] Its use for other medical applications is insufficient for conclusions about safety or efficacy.

The first of Berenson’s questions concerns what has long been the most worrisome point about cannabis: its association with mental illness. Many people with serious psychiatric illness smoke lots of pot. The marijuana lobby typically responds to this fact by saying that pot-smoking is a response to mental illness, not the cause of it—that people with psychiatric issues use marijuana to self-medicate. That is only partly true. In some cases, heavy cannabis use does seem to cause mental illness. As the National Academy panel declared, in one of its few unequivocal conclusions, “Cannabis use is likely to increase the risk of developing schizophrenia and other psychoses; the higher the use, the greater the risk.”

Hemp Oil

×